AOTMiT: The Transparency Council will evaluate drugs and health programs

The agenda includes:

1 Prepare an opinion on reimbursement in off-label indications of drugs containing the following active substances:

Agomelatine for the indication: depression or depressive disorders - until the age of 18,

Aripiprazole for the indication: depression or depressive disorders, obsessive-compulsive disorder (F42), tics (F95.0; F95.1; F95.8, F95.9) - until the age of 18,

Duloxetine for the indication: anxiety and adjustment disorders - until the age of 18,

Clonazepam for the indication: attention deficit hyperactivity disorder (ADHD, F90.1), tics (F95.0; F95.1; F95.8, F95.9), Tourettes syndrome (F95.2) - until the age of 18, Quetiapine for the indication: depression or depressive disorder - until the age of 18,

Olanzapine for the indication: mental anorexia nervosa (F50.0) - until the age of 18,

Risperidone for the indication: depression or depressive disorders, tics (F95.0; F95.1; F95.8, F95.9) - until age 18,

Sulpiride for the indication: tics (F95.0; F95.1; F95.8, F95.9) - until age 18,

Topiramate for the indication: tics (F95.0; F95.1; F95.8, F95.9) - until age 18,

Ziprazidone for the indication: tics (F95.0; F95.1; F95.8, F95.9) - until age 18.

2 Prepare an opinion on the draft health policy program "Regional Health Program - Curative rehabilitation of oncology patients in the West Pomeranian province".

3 To prepare an opinion on the draft health policy program "Prevention of depressive disorders for children and adolescents aged 12-26 in the Municipality of Józefów for 2024-2025".

4 Prepare an opinion on the draft health policy program "Dental Prevention Health Program in the Municipality of Gostycyn for 2024-2027".

Source: AOTMiT